thought call
share overreact underli growth remain intact given known headwind
consensu estim alreadi embed organ sale
growth includ moder pharma growth view today stock move
reflect chang sentiment perceiv risk real deterior
jnj fundament dont see problem pharma per se anoth remicad
biosimilar along tracleer procrit gener wide expect though
zytiga fate remain unclear could potenti maintain better expect share
prostat long-term combin apalutamid niraparib
rather issu build growth driver like tremfya actelion
yet scale label expans former latter aprocitentan
impact dont expect rel multipl contract much
given earn growth year better pharma perform remain
key share continu upward run maintain equal weight pt
upcom oncolog catalyst could firm growth pictur spartan data
gu clarifi pre-metastat opportun apalutamid
stack vs current therapi darzalex expect move front-lin set
alcyon maia transit subcutan formul
combin potenti solid tumor could also start enter discuss
medic devic consum pick momentum neither medic
devic consum expect sharp growth inflect year
potenti divest diabet babi re-launch reson
consum partli help mitig concern pharma
model chang weve rais sale report
organ growth unchang pre-tax margin expect increas bp
spite higher spend bp cut tax rate primarili
drive new ep estim chang similarli
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight think outlook intact
recent success pharmaceut broader
move away defens stock less like
result share continu outperform
remicad biosimilar moder pipelin
potenti slow medic devic util full
consum stapl valuat make
could use substanti balanc sheet
acquisit fuel faster expect growth
consum margin could improv quickli
medic devic share growth could acceler
pharmceut pipelin expect may
conserv
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commer success medic devic
util deceler consum margin
expand quickli could result downward
pressur share price
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
geoff meacham ph paul choi herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli
indirectli relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
